Yüklüyor......
SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
Denosumab (DMAb) is a soluble inhibitor of RANKL and, therefore, does not incorporate into the bone matrix. Consistently, DMAb discontinuation is associated with the reversal of the effects attained with treatment. Concerns have been raised regarding possible increased vertebral fragility following...
Kaydedildi:
| Yayımlandı: | J Endocr Soc |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Endocrine Society
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552094/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-532 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|